Entera Bio Ltd. (FRA:5DT)

Market Cap	46.57M -31.3%
Revenue (ttm)	35.77K -76.8%
Net Income	-9.74M
EPS	-0.21
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	204
Open	0.9600
Previous Close	1.0200
Day's Range	0.9450 - 0.9650
52-Week Range	0.8400 - 2.6600
Beta	n/a
RSI	51.38
Earnings Date	May 14, 2026

About Entera Bio

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist pept...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5DT

Financial Performance

In 2025, Entera Bio's revenue was $42,000, a decrease of -76.80% compared to the previous year's $181,000. Losses were -$11.44 million, 19.9% more than in 2024.

Financial numbers in USD